Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus selective serotonin reuptake inhibitor (SSRI) [serotonin reuptake inhibitors]. Six-week treatment plus optional continuation for 18 weeks

Trial Profile

Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus selective serotonin reuptake inhibitor (SSRI) [serotonin reuptake inhibitors]. Six-week treatment plus optional continuation for 18 weeks

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Agomelatine; Sertraline
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2010 Results published in the Journal of Clinical Psychiatry.
    • 01 Feb 2010 Primary endpoint 'Sleep measures' has been met.
    • 01 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top